HOME >> BIOLOGY >> NEWS
Ohio State chemists synthesize possible new anti-tumor agent

behind azinomycin A so that we can develop more effective anti-tumor agents in the future."

Coleman said an enhanced version of azinomycin A might make an especially potent chemotherapy agent. He pointed to laboratory tests from 1987, when Japanese scientists found that the short-lived natural version of the chemical attacked tumor cells in a test tube and was effective as combating cancer in animal models.

Scientists now believe azinomycin A and its sibling azinomycin B -- both produced by a type of Streptomyces soil bacteria - attack DNA by forming very strong bonds, and are two of only a handful of chemicals that bond to DNA in this way.

In 1989, Coleman first began to design the chemical steps needed to synthesize azinomycin A and B in the laboratory. He started the work at the University of South Carolina and, beginning in 1996, at Ohio State.

Over that time, several researchers contributed to the project. In particular, Coleman credits Andrew Carpenter and Thomas Richardson, both his former Ph.D. students, and Jian-She Kong, an Ohio State postdoctoral researcher in chemistry, with performing important preliminary studies. The Ohio State work in the Angewandte Chemie paper was done by Coleman's co-authors, Jing Li and Antonio Navarro, both postdoctoral researchers.

Coleman and his colleagues devised a strategy for breaking the complex-shaped azinomycin A molecule int
'"/>

Contact: Robert Coleman
Coleman.184@osu.edu
614-292-4548
Ohio State University
1-May-2001


Page: 1 2 3

Related biology news :

1. New Arizona State center brings science to policy on issues of water resources and urban growth
2. K-State, other universities to study how climate affects plant evolution
3. K-States National Agricultural Biosecurity Center receives $1.3 Million from Department of Defense
4. K-State professor combines love of teaching, research to examine eye development
5. K-State researcher working to improve alternatives to equine antibiotics
6. Lung cancer patients in Japan, United States react differently to the same chemotherapy regimen
7. K-State business researchers to help with major study on food supply veterinary medicine
8. K-State researchers share $1 million grant to study insect pests
9. UC Riverside professor to spend year with US State Department
10. American Lung Associations 2004 State of the Air report ranks cities and counties with dirty air
11. K-State soil carbon sequestration research playing role in climate change efforts

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/12/2019)... GREEN, Ohio (PRWEB) , ... ... ... Engineered Products , a global leader in the design and manufacturer of ... selection of seating and adjustable footrests compliant with Healthier Hospital Initiative guidelines. ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... microbial identification, played a key role in the award-winning study “Next Generation Sequencing ... Rothman Institute. The molecular diagnostic laboratory processed samples using Next Generation DNA Sequencing ...
(Date:11/6/2019)... (PRWEB) , ... November 06, 2019 , ... ... that Donald Stanski, MD, a senior pharmaceutical industry executive with expertise in clinical ... simulation for drug and disease strategic data analytics, has joined the firm as ...
Breaking Biology News(10 mins):
(Date:10/22/2019)... ... 22, 2019 , ... Catalent, a global leader in clinical supply services, today ... will participate in a panel session titled “Cell and Gene Therapy Logistics” at the ... Hotel, Chicago, on Oct. 28-30, 2019. , The panel session, on Wednesday, Oct. 30 ...
(Date:10/22/2019)... ... October 22, 2019 , ... DermBiont, ... its lead program, DBI-001, met its primary safety endpoints, with no application site ... clinical trial for the treatment of interdigital tinea pedis (athlete’s foot). Additionally, the ...
(Date:10/17/2019)... ... 16, 2019 , ... My Gene Counsel , a ... a new white paper that explores how frequently medical management guidelines have been ... and medical providers can be kept informed as changes are made. , Entitled ...
(Date:10/10/2019)... Md. (PRWEB) , ... October 09, 2019 , ... ... announced Amy Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a newly-confirmed keynote ... 27–30 October 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist ...
Breaking Biology Technology:
Cached News: